Last reviewed · How we verify
NCT06463821
Symptom Spectrum and Risk Factors for Fever in Pediatric and Adult Patients With Omicron Infection
trial testing observational questionnaires in Symptom Spectrum and Risk Factors for Fever in 2,591 participants. Completed in 17 May 2022.
17 May 2022
Quick facts
| Lead sponsor | Shanghai Children's Medical Center |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 2,591 |
| Start date | 8 April 2022 |
| Primary completion | 17 May 2022 |
| Estimated completion | 17 May 2022 |
| Sites | 1 location across China |
Drugs / interventions tested
- observational questionnaires
Conditions studied
- Symptom Spectrum and Risk Factors for Fever — all drugs for Symptom Spectrum and Risk Factors for Fever →
Sponsor
Shanghai Children's Medical Center
Who can join
0 and older, any sex, with Symptom Spectrum and Risk Factors for Fever. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The omicron variant of coronavirus disease 2019 (COVID-19) has caused a global epidemic in 2022. The aim was to investigate the symptom spectrum and risk factors for fever in pediatric and adult patients with omicron infection. From April 8, 2022 to May 17, 2022, this prospective observational study included patients who attended the child-parent sections of the Fangcang shelter hospitals with laboratory-confirmed COVID-19. Patient data were collected from questionnaires. The risk factors for prolonged fever and high fever were identified by univariate and multivariate analyses.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT06463821
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Shanghai Children's Medical Center trials
Trials by the same sponsor.
- NCT07383883 — Multimodal Tongue-Pulse Information Fusion for Syndrome Diagnosis and Cohort Study in Children With Asthma · recruiting
- NCT07035821 — Olanzapine for Prevention of Vomiting in Children and Adolescents Receiving Highly Emetogenic Chemotherapy · Phase 3 · not yet recruiting
- NCT07003126 — A Cohort Study on Treating Primary Nocturnal Enuresis by Regulating Central-Peripheral Circadian Rhythm · NA · not yet recruiting
- NCT07351955 — Clinical Study on a Novel Strategy of Individualized Non-Invasive Neuromodulation for the Treatment of Tic Disorders in · NA · recruiting
- NCT07000656 — Micturition Desire-Relaxation Training Device for Lower Urinary Tract Dysfunction in Children · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06463821 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Shanghai Children's Medical Center
- Last refreshed: 18 June 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06463821.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing